Applied BioCode (6598) Stock Overview
Designs, develops, and commercializes multiplex diagnostic testing products in California. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6598 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Applied BioCode Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.15 |
| 52 Week High | NT$31.90 |
| 52 Week Low | NT$20.50 |
| Beta | 0.63 |
| 1 Month Change | -2.34% |
| 3 Month Change | 11.27% |
| 1 Year Change | 17.53% |
| 3 Year Change | 13.36% |
| 5 Year Change | -25.41% |
| Change since IPO | -60.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6598 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -4.4% | -1.6% | -3.1% |
| 1Y | 17.5% | -21.4% | 78.6% |
Return vs Industry: 6598 exceeded the TW Medical Equipment industry which returned -21.4% over the past year.
Return vs Market: 6598 underperformed the TW Market which returned 78.6% over the past year.
Price Volatility
| 6598 volatility | |
|---|---|
| 6598 Average Weekly Movement | 7.8% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in TW Market | 11.2% |
| 10% least volatile stocks in TW Market | 2.4% |
Stable Share Price: 6598 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6598's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Winston Z. Ho | www.apbiocode.com |
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products.
Applied BioCode Corporation Fundamentals Summary
| 6598 fundamental statistics | |
|---|---|
| Market cap | NT$2.85b |
| Earnings (TTM) | -NT$48.89m |
| Revenue (TTM) | NT$666.54m |
Is 6598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6598 income statement (TTM) | |
|---|---|
| Revenue | NT$666.54m |
| Cost of Revenue | NT$251.50m |
| Gross Profit | NT$415.04m |
| Other Expenses | NT$463.93m |
| Earnings | -NT$48.89m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 62.27% |
| Net Profit Margin | -7.33% |
| Debt/Equity Ratio | 0% |
How did 6598 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 12:18 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied BioCode Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Investment Advisory |